

#### GlaxoSmithKline UK Ltd

Stockley Park West Uxbridge Middlesex UB11 1BT

Tel. +44 (0)20 8990 9000 Fax. +44 (0)20 8990 4321 www.gsk.com

## IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS

### 1<sup>st</sup> December 2018

Dear Healthcare Professional,

# Notification of discontinuation of Zovirax (Aciclovir) Eye Ointment (3% w/w)

INDICATIONS: Zovirax Eye Ointment is an antiviral ointment indicated for the treatment of herpes simplex keratitis

- GSK will cease the manufacture and supply of Zovirax Eye Ointment globally during 2018 due to repeated challenges in guaranteeing a sustainable product supply. GSK regrets that it has no alternative but to discontinue this product.
- This decision has not been taken due to safety concerns.
- There is no other branded or generic aciclovir eye ointment available. Please refer to the UKMI memo on the discontinuation of Zovirax Eye Ointment for further information on alternative treatment options.
- Stock of Zovirax Eye Ointment is anticipated to continue to be available in the UK until the end of **June 2019**, subject to demand.
- GSK offers its sincerest apologies to patients and healthcare professtionals for the impact that this may have.



## Action Being Taken by GlaxoSmithKline

This information is being communicated to appropriate regulatory authorities and healthcare professionals.

Sufficient stock has been manufactured to last until 30<sup>th</sup> June 2019 at the current rate of demand. If the demand should vary, it is possible that supplies could become exhausted before the end of June, or could last beyond the end of June.

## **Action required by Healthcare Providers**

Please share this information with relevant healthcare personnel under your supervision and explore other options for patient management. Please refer to the UKMI Memo on the discontinuation of Zovirax Eye Ointment for further information.

GSK is providing a 6 month notice period, ahead of the discontinuation, to enable healthcare professionals to transfer patients onto alternative treatments. The MHRA has also been informed.

### **Further Information**

For further information, please see the UKMI Memo on the discontinuation of Zovirax Eye Ointment at <a href="https://www.sps.nhs.uk/articles/shortage-of-aciclovir/">https://www.sps.nhs.uk/articles/shortage-of-aciclovir/</a>, or contact the GSK Medical Information Department on <a href="https://www.sps.nhs.uk/articles/shortage-of-aciclovir/">0800 221 441 (option 2)</a>.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Yours sincerely,

Dr Karen Mullen MBBS MRCP MFPM

Vice President

Country Medical Director UK & Ireland